

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
May 2, 2007
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 2, 2007.

2. Welcome

Dr. LaCroix called the meeting to order and welcomed members, guests, and staff members.

Dr. LaCroix opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Ed Behling, M.D.

Gregory V. Browning, M.D.

Charmaine George, M.D.

Kelly Jones, Pharm.D.

Robin K. LaCroix, M.D.

Jim Lindsay, M.D.

Sara Lindsey, M.D.

Tan Platt, M.D.

Deborah J. Tapley, R.Ph.

George E. Vess, Pharm. D.

Thomas Phillips, R.Ph.

DHHS Staff Present:

Marion Burton, M.D.

James M. Assey, R.Ph.

April Smith

Richard Hepfer, J.D.

Other Representation:

First Health Services. – Mary Roberts, R.Ph.

Pharmaceutical Industry Speakers

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, February 7, 2006.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

The rules for public comment were outlined. Dr. LaCroix instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

Company	Speaker	Drug
Astra Zeneca	Sonja Grooms-Smith, PhD Senior Regional Scientific Manager Cardiovascular Medical Affairs AstraZeneca	Crestor®
Pfizer	J. William (Bill) Phillips III, M.D. Vice Chief of Cardiac Services, Palmetto Richland Memorial Hospital, Director of Medical Education and Cardiovascular Research, Columbia Heart Clinic	Lipitor®
Schering Plough	Donald R. Williams, Pharm.D., MBA Cardiovascular Medical Science Liaison Global Medical Affairs Schering-Plough Corporation	Vytorin®
Schering Plough	John F. Howard, Pharm. D. Medical Science Specialist Schering-Plough Corporation	Proventil HFA®
Sanofi-Aventis	Michelle Warren Welborn, Pharm. D. Regional Medical Liaison Sanofi-Aventis Pharmaceuticals, Inc	Lantus®
Serono	Kelly Behm R.N. Nurse Consultant Clinical Endocrinology and Research	Saizen®

C. Public Comment Physician Presentation

David Schwartz, M.D. spoke to the committee regarding the use of growth hormone in the pediatric population. Dr. Schwartz represented no particular growth hormone product or pharmaceutical manufacturer. Although Dr. Schwartz's comments were his own, he felt his comments represented the thinking of the other pediatric endocrinology specialist in the state.

D. Drug Classes for Review and Re-Review

Mary Roberts, R.Ph., First Health Services Corporation, led the discussion for the following drug classes:

- Carbamazepine Derivatives
- Low Molecular Weight Heparins
- Growth Hormone
- High Potency Statins
- Short Acting Beta Adrenergics
- Long Acting Insulins

The chart below represents the recommendations for the P & T Committee:

NO PA REQUIRED "PREFERRED"	PA REQUIRED
<i>Carbamazepine Derivatives</i>	
CARBAMAZEPINE (TABLETS, CHEWABLES, AND SUSPENSION) CARBATROL® EPITOL® TEGRETOL XR® TRILEPTAL® (TABLETS AND SUSPENSION)	TEGRETOL® (TABLETS, CHEWABLES, AND SUSPENSION)
<i>Low Molecular Weight Heparins</i>	
ARIXTRA® FRAGMIN® LOVENOX®	INNOHEP®
<i>Growth Hormone</i>	
GENOTROPIN® NORDITROPIN® SAIZEN®	HUMATROPE® NUTROPIN® OMNITROPE® TEV-TROPIN®
<i>High Potency Statins</i>	
CRESTOR® LIPITOR® VYTORIN® SIMVASTATIN	ZOCOR®
<i>Short Acting Beta Adrenergics</i>	
ALBUTEROL CFC ONE ALBUTEROL HFA (specific agent to be determined by DHHS) XOPENEX HFA®	ALUPENT® MAXAIR® PROAIR HFA® PROVENTIL HFA® VENTOLIN HFA®
<i>Long Acting Insulins</i>	
LEVEMIR® VIAL LANTUS® VIAL	LEVEMIR® PEN LANTUS® CARTRIDGE

5. **Old Business**

No old business.

6. **New Business**

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

- Carbamazepine Derivatives
- Low Molecular Weight Heparins
- Growth Hormone
- High Potency Statins
- Short Acting Beta Adrenergics
- Long Acting Insulins

8. **Closing Comments**

The next meeting will be held on Wednesday, August 1, 2007 at 4:00 p.m. at the same location.

9. **Adjournment**

The meeting adjourned at 5:45p.m.